Lebowitz Steven, Kowalewski Mariusz, Raffa Giuseppe Maria, Chu Danny, Greco Matteo, Gandolfo Caterina, Mignosa Carmelo, Lorusso Roberto, Suwalski Piotr, Pilato Michele
University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA.
Cardio-Thoracic Surgery Department, Heart and Vascular Centre, Maastricht University Medical Centre (MUMC), 6200 MD Maastricht, The Netherlands.
J Clin Med. 2022 Jun 14;11(12):3405. doi: 10.3390/jcm11123405.
Hypertrophic obstructive cardiomyopathy (HOCM) is a heterogeneous disease with different clinical presentations, albeit producing similar dismal long-term outcomes if left untreated. Several approaches are available for the treatment of HOCM; e.g., alcohol septal ablation (ASA) and surgical myectomy (SM). The objectives of the current review were to (1) discuss the place of the standard invasive treatment modalities (ASA and SM) for HOCM; (2) summarize and compare novel techniques for the management of HOCM; (3) analyze current guidelines addressing HOCM management; and (4) offer suggestions for the treatment of complex HOCM presentations.
We searched the literature and attempted to gather the most relevant and impactful available evidence on ASA, SM, and other invasive means of treatment of HOCM. The literature search yielded thousands of results, and 103 significant publications were ultimately included.
We critically analyzed available guidelines and provided context in the setting of patient selection for standard and novel treatment modalities. This review offers the most comprehensive analysis to-date of available invasive treatments for HOCM. These include the standard treatments, SM and ASA, as well as novel treatments such as dual-chamber pacing and radiofrequency catheter ablation. We also account for complex pathoanatomic presentations and current guidelines to offer suggestions for tailored care of patients with HOCM. Finally, we consider promising future therapies for HOCM.
HOCM is a heterogeneous disease associated with poor outcomes if left untreated. Several strategies for treatment of HOCM are available but patient selection for the procedure is crucial.
肥厚型梗阻性心肌病(HOCM)是一种具有不同临床表现的异质性疾病,尽管未经治疗时会产生相似的不良长期预后。有几种方法可用于治疗HOCM;例如,酒精室间隔消融术(ASA)和外科室间隔心肌切除术(SM)。本综述的目的是:(1)讨论标准侵入性治疗方式(ASA和SM)在HOCM治疗中的地位;(2)总结和比较HOCM管理的新技术;(3)分析当前关于HOCM管理的指南;(4)为复杂HOCM表现的治疗提供建议。
我们检索了文献,并试图收集关于ASA、SM和其他侵入性HOCM治疗方法的最相关且有影响力的现有证据。文献检索产生了数千条结果,最终纳入了103篇重要出版物。
我们严格分析了现有指南,并在标准和新治疗方式的患者选择背景下提供了相关情况。本综述对目前可用的HOCM侵入性治疗进行了迄今为止最全面的分析。这些治疗包括标准治疗方法SM和ASA,以及双腔起搏和射频导管消融等新治疗方法。我们还考虑了复杂的病理解剖表现和当前指南,为HOCM患者的个性化护理提供建议。最后,我们考虑了HOCM未来有前景的治疗方法。
HOCM是一种异质性疾病,若不治疗,预后较差。有几种治疗HOCM的策略,但手术的患者选择至关重要。